Overview

NSAID Effects on Clinical and Imaging Breast Biomarkers

Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Stony Brook University
Treatments:
Aromatase Inhibitors
Sulindac